Enpp-1-IN-25

Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy[1].

Product Specifications

CAS Number

[3067908-20-4]

UNSPSC

12352005

Target

PD-1/PD-L1; Phosphodiesterase (PDE) ; STING

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

COC1=C(C2=CC=C1)N=CN=C2N3CCC(CNS(=O)(N)=O)(CC3)O

Molecular Formula

C15H21N5O4S

Molecular Weight

367.42

References & Citations

[1]He J, et al. Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy. J Med Chem. 2025 Feb 20.